2.Corbett, EL, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 2003; 163: 1009–1021.
3.Dye, C, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Journal of the American Medical Association 1999; 282: 677–686.
4.Broekmans, JF, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. European Respiratory Journal 2002; 19: 765–775.
5.Jasmer, RM, Nahid, P, Hopewell, PC. Clinical practice. Latent tuberculosis infection. New England Journal of Medicine 2002; 347: 1860–1866.
6.American Thoracic Society/Centers for Disease Control and Prevention.Targeted tuberculin testing and treatment of latent tuberculosis infection. American Journal of Respiratory and Critical Care Medicine 2000; 161: S221–247.
7.Menzies, D, Pai, M, Comstock, G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of Internal Medicine 2007; 146: 340–354.
8.Pai, M, Zwerling, A, Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of Internal Medicine 2008; 149: 177–184.
9.Bakir, M, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Annals of Internal Medicine 2008; 149: 777–787.
10.Yoshiyama, T, et al. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. International Journal of Tuberculosis and Lung Disease 2010; 14: 819–827.
11.Kik, SV, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. European Respiratory Journal 2010; 35: 1346–1353.
12.Diel, R, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine 2008; 177: 1164–1170.
13.Mori, T, Harada, N. Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Kekkaku 2005; 80: 675–686.
14.Menzies, D, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of Internal Medicine 2008; 149: 689–697.
15.Menzies, D, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. American Journal of Respiratory and Critical Care Medicine 2004; 170: 445–449.
16.Blumberg, HM, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003; 167: 603–662.
17.Holdiness, MR. A review of blood dyscrasias induced by the antituberculosis drugs. Tubercle and lung disease 1987; 68: 301–309.
18.Livengood, JR, et al. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. Journal of the American Medical Association 1985; 253: 2847–2849.
19.Balcells, ME, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerging Infectious Diseases 2006; 12: 744–751.
20.Lee, SH, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respiratory Medicine 2010; 104: 448–453.
21.Korea Center for Disease Control. National guidelines for managing tuberculosis. KCDC guideline 2007, pp. 133–141.
22.Grosset, J, Leventis, S. Adverse effects of rifampin. Reviews of Infectious Diseases 1983; 5: S440–S450.
23.Blajchman, MA, et al. Rifampicin-induced immune thrombocytopenia. British Medical Journal 1970; 3: 24–26.
24.Martnez, E, Collazos, J, Mayo, J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine 1999; 78: 361–369.
25.Girling, DJ. Adverse reactions to rifampicin in antituberculosis regimens. Journal of Antimicrobial Chemotherapy 1977; 3: 115–132.
26.LoBue, PA, Moser, KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine 2003; 168: 443–447.
27.Lobue, P, Menzies, D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15: 603–622.
28.Anon.A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. American Review of Respiratory Disease 1992; 145: 36–41.
29.Villarino, ME, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. American Journal of Respiratory and Critical Care Medicine 1997; 155: 1735–1738.
30.Polesky, A, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. American Journal of Respiratory and Critical Care Medicine 1996; 154: 1473–1477.
31.Nolan, CM, et al. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. American Review of Respiratory Disease 1986; 133: 431–436.
32.Bai, GH, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994–2004. International Journal of Tuberculosis and Lung Disease 2007; 11: 571–576.
33.Lee, S, et al. The role of chest CT scanning in TB outbreak investigation. Chest 2010; 137: 1057–1064.